Dyslexia Treatment Market is driven by Increasing Prevalence of Dyslexia
The Global dyslexia treatment market is estimated to be valued at US$ 7.59 Bn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period from 2024 to 2031. The increasing prevalence of dyslexia worldwide along with growing awareness levels regarding learning disabilities are major factors driving the growth of the dyslexia treatment market. Furthermore, the development of novel treatment methods such as stem cell therapy and neurofeedback therapy is also contributing to the market growth.
Key Takeaways
Key players operating in the dyslexia treatment market are Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, Astrazeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Lupin. Key players are focusing on developing advanced treatment methods and focusing on underpenetrated markets to strengthen their positions in the market.
The growing prevalence of dyslexia across both developed and developing economies is augmenting the demand for effective Dyslexia Treatment Market Growth options. According to studies, dyslexia affects nearly 10% of people worldwide. Early diagnosis and intervention can help improve reading abilities and self-esteem in people with dyslexia.
Growing awareness regarding learning disabilities along with the de-stigmatization of dyslexia is encouraging more people to seek formal evaluation and treatment. Furthermore, with rising education levels combined with greater access to screening and healthcare services in emerging nations, the dyslexia treatment market is expected to witness significant gains in Asia Pacific and Latin America over the forecast period.
Market Drivers
The increasing prevalence of dyslexia across all age groups is a key factor driving the need for effective dyslexia treatment options. Studies show that dyslexia is quite common and affects nearly 1 in 5 individuals. At present, there is no permanent cure for dyslexia but early diagnosis and intervention through specialized educational programs and therapies can help people with dyslexia overcome difficulties in reading and writing. Furthermore, innovative solutions such as medications, audio therapy, neurofeedback are expanding the treatment avenues for dyslexia, thereby propelling the market growth.
Get more insights on Dyslexia Treatment Market
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian